Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Rating of “Hold” by Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $12.3750.

A number of equities research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, December 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Jefferies Financial Group reissued a “hold” rating and issued a $7.50 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday. B. Riley initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, November 5th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 8th.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $7.03 on Wednesday. The company has a quick ratio of 3.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $5.52 and its two-hundred day moving average is $5.02. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $7.47. The company has a market capitalization of $415.47 million, a PE ratio of -4.95 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The company had revenue of $56.26 million for the quarter, compared to analysts’ expectations of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%. As a group, analysts expect that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VNDA. Russell Investments Group Ltd. lifted its position in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares during the period. CWM LLC raised its stake in Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 7,575 shares in the last quarter. PVG Asset Management Corp purchased a new stake in Vanda Pharmaceuticals during the first quarter worth $48,000. Quarry LP bought a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at $53,000. Finally, Cerity Partners LLC bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at $69,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.